Supplement of

The efficacy of suppressive antibiotic treatment in patients managed non-operatively for periprosthetic joint infection and a draining sinus

Karel-Jan Dag François Lensen et al.

Correspondence to: Marjan Wouthuyzen-Bakker (m.wouthuyzen-bakker@umcg.nl)

The copyright of individual parts of the supplement might differ from the article licence.
### Antibiotic

| Antibiotic                        | First SAT       | Second SAT      | Third SAT       |
|-----------------------------------|-----------------|-----------------|-----------------|
| Sulfamethoxazol-trimethoprim      | 16/63 (25.4%)   | 16/38 (42.1%)   | 4/18 (22.2%)    |
| Amoxicillin                       | 5/63 (7.9%)     | 0/38 (0%)       | 0/18 (0%)       |
| Amoxicillin-clavulanic acid       | 3/63 (4.7%)     | 3/38 (7.9%)     | 1/18 (5.6%)     |
| Ciprofloxacin                     | 7/63 (11.1%)    | 3/38 (7.9%)     | 0/18 (0%)       |
| Levofloxacin                      | 4/63 (6.3%)     | 0/38 (0%)       | 1/18 (5.6%)     |
| Doxycyclin                        | 6/63 (9.5%)     | 0/38 (0%)       | 2/18 (11.1%)    |
| Clindamycin                       | 4/63 (6.3%)     | 4/38 (10.5%)    | 2/18 (11.1%)    |
| Minocyclin                        | 4/63 (6.3%)     | 1/38 (2.6%)     | 0/18 (0%)       |
| Cefadrox                          | 2/63 (3.2%)     | 1/38 (2.6%)     | 1/18 (5.6%)     |
| Other*                            | 12/63 (19.3%)   | 10/38 (16.3%)   | 7/18 (38.9%)    |

**Supplemental Table 1.** The prescription of suppressive antibiotic treatment (SAT). The Table indicates different regimens used per individual (First, second and third period).

### Adverse event

| Adverse event          | First SAT       | Second SAT      | Third SAT       |
|------------------------|-----------------|-----------------|-----------------|
| Total number           | 17/63 (27.0%)   | 8/37 (21.6%)    | 4/18 (22.2%)    |
| Specified              |                 |                 |                 |
| Gastro-intestinal      | 10/63 (15.9%)   | 1/37 (2.6%)     | 1/18 (5.6%)     |
| Hematological          | 2/63 (3.2%)     | 2/37 (5.3%)     | 2/18 (11.1%)    |
| Musculoskeletal        | 2/63 (3.2%)     | 0/37 (0%)       | 0/18 (0%)       |
| Dermatological         | 2/63 (3.2%)     | 0/37 (0%)       | 0/18 (0%)       |
| Allergy                | 0/63 (0%)       | 4/37 (10.5%)    | 0/18 (0%)       |
| Other                  | 1/63 (1.6%)     | 1/37 (2.6%)     | 1/18 (5.6%)     |

**Supplemental Table 2.** Adverse events in PJI patients with a draining sinus on suppressive antibiotic treatment (SAT). The Table indicates different regimens used per individual (First, second and third period).